In the USA, companies usually file for a IND (Investigational New Drug) with the FDA. Replicor, being a Canadian company, the process may be different.
Thank you very much for this update, hope all goes on well with the trial. Back in Oct 2013 in the HB advocate article the company said they "hope the European study will be the last piece of confirmation work they would need before initiating the registration of this therapy (rep 9ac + peg + Nuc)". Anyone got an idea what this "registration of this therapy" means? and what's expected to follow after the European study, a Stage II clinical trial?
Any idea what this trial involves? What is it trying to establish?
Thanks
Very glad to hear. Can't wait for more good news. Thanks for posting!